Alpha Tau Medical (DRTS)
Develops Alpha DaRT, a localized alpha-radiation therapy for solid tumors.
$15.08
After hours−0.07 (−0.48%)
At close$15.15(−2.26%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 9 | 9 | 8 | 9 | 8 | 10 | 9 | 10 | 11 | 13 | 13 | 14 | |
| Research & development | 7 | 7 | 6 | 7 | 6 | 8 | 7 | 7 | 8 | 10 | 11 | 10 |
| 2 | 2 | 2 | 2 | 2 | 3 | 2 | 3 | 2 | 3 | 2 | 4 | |
| Selling & marketing | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 0 | 3 | 2 | 4 |
| Other expenses | 0 | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −9 | −10 | −8 | −9 | −8 | −10 | −9 | −10 | −11 | −13 | −13 | −14 |
| 4 | 3 | 0 | 2 | 1 | 1 | 1 | 0 | −1 | 0 | −10 | −32 | |
| Interest income | 0 | 1 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 32 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | −5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −5 | −7 | −8 | −7 | −7 | −9 | −9 | −10 | −12 | −12 | −23 | −46 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −5 | −7 | −8 | −7 | −7 | −9 | −9 | −10 | −12 | −12 | −23 | −46 |
| Net income | −5 | −7 | −8 | −7 | −7 | −9 | −9 | −10 | −12 | −12 | −23 | −46 |
| EPS, basic | −$0.07 | −$0.11 | −$0.11 | −$0.11 | −$0.10 | −$0.14 | −$0.12 | −$0.13 | −$0.14 | −$0.14 | −$0.26 | −$0.50 |
| EPS, diluted | −$0.07 | −$0.11 | −$0.11 | −$0.11 | −$0.10 | −$0.14 | −$0.12 | −$0.13 | −$0.14 | −$0.14 | −$0.26 | −$0.50 |
| Weighted average shares, basic | 69 | 70 | 70 | 70 | 70 | 70 | 70 | 80 | 85 | 86 | 90 | 91 |
| Weighted average shares, diluted | 69 | 70 | 70 | 70 | 70 | 70 | 70 | 80 | 85 | 86 | 90 | 91 |
| EBITDA | −9 | −9 | −8 | −9 | −8 | −5 | −9 | −9 | −11 | −11 | −13 | −14 |
| Depreciation & amortization | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| EBIT | −9 | −10 | −8 | −9 | −8 | −6 | −9 | −9 | −11 | −12 | −13 | −14 |
